Journal of Drug Delivery Science and Technology, Год журнала: 2024, Номер unknown, С. 106559 - 106559
Опубликована: Дек. 1, 2024
Язык: Английский
Molecular Therapy — Methods & Clinical Development, Год журнала: 2025, Номер 33(1), С. 101436 - 101436
Опубликована: Фев. 16, 2025
Lipid nanoparticles (LNPs) are now highly effective transporters of nucleic acids to the liver. This liver-specificity is largely due their association with certain serum proteins, most notably apolipoprotein E (ApoE), which directs them liver cells by binding low-density lipoprotein (LDL) receptors on hepatocytes. The liver's distinct anatomy, its various specialized cell types, also influences how LNPs taken up from circulation, cleared, and they in delivering treatments. In this review, we consider factors that facilitate LNP's targeting explore latest advances liver-targeted LNP technologies. Understanding targeted can help for design optimization nanoparticle-based therapies. Comprehension cellular interaction biodistribution not only leads better treatments diseases but delivers insight directing other tissues, potentially broadening range therapeutic applications.
Язык: Английский
Процитировано
5
Journal of Nanobiotechnology, Год журнала: 2024, Номер 22(1)
Опубликована: Июнь 28, 2024
Abstract Lipid nanoparticles (LNPs) have proven themselves as transformative actors in chimeric antigen receptor (CAR) T cell therapy, surpassing traditional methods and addressing challenges like immunogenicity, reduced toxicity, improved safety. Promising preclinical results signal a shift toward safer more effective CAR treatments. Ongoing research aims to validate these findings clinical trials, marking new era guided by LNPs utility therapy. Herein, we explore the preference for over methods, highlighting versatility of their delivery nucleic acids. Additionally, address key considerations, heralding Graphical
Язык: Английский
Процитировано
12
Pharmaceuticals, Год журнала: 2024, Номер 17(8), С. 1070 - 1070
Опубликована: Авг. 15, 2024
The blood–cerebrospinal fluid barrier (BCSFB) tightly regulates molecular exchanges between the bloodstream and cerebrospinal (CSF), creating challenges for effective central nervous system (CNS) drug delivery. This review assesses intrathecal (IT) nanoparticle (NP) delivery systems that aim to enhance by circumventing BCSFB, complementing approaches target blood–brain (BBB). Active pharmaceutical ingredients (APIs) face hurdles like restricted CNS distribution rapid clearance, which diminish efficacy of IT therapies. NPs can be engineered extend circulation times, improve penetration, facilitate sustained release. discusses key pharmacokinetic (PK) parameters essential effectiveness these systems. quickly traverse subarachnoid space remain within leptomeninges extended periods, often exceeding three weeks. Some designs enable deeper brain parenchyma penetration. Approximately 80% in CSF are cleared through perivascular glymphatic pathway, with microglia-mediated transport significantly contributing their paravascular clearance. synthesizes recent progress IT-NP across highlighting critical findings, ongoing challenges, therapeutic potential surface modifications targeted strategies.
Язык: Английский
Процитировано
12
Journal of Nanotheranostics, Год журнала: 2025, Номер 6(2), С. 10 - 10
Опубликована: Апрель 9, 2025
Nanotheranostics—where nanoscale materials serve both diagnostic and therapeutic functions—are rapidly transforming gene therapy by tackling critical delivery challenges. This review explores the design engineering of various nanoparticle systems (lipid-based, polymeric, inorganic, hybrid) to enhance stability, targeting, endosomal escape genetic payloads. We discuss how real-time imaging capabilities integrated into these platforms enable precise localization controlled release genes, improving treatment efficacy while reducing off-target effects. Key strategies overcome barriers (such as proton sponge effect photothermal disruption) achieve nuclear are highlighted, along with recent advances in stimuli-responsive that facilitate spatiotemporal control expression. Clinical trials preclinical studies demonstrate expanding role nanotheranostics managing cancer, inherited disorders, cardiovascular neurological diseases. further address regulatory manufacturing hurdles must be for widespread clinical adoption nanoparticle-based therapies. By synthesizing progress ongoing challenges, this underscores transformative potential effective, targeted, image-guided delivery.
Язык: Английский
Процитировано
2
Neural Regeneration Research, Год журнала: 2024, Номер 20(6), С. 1665 - 1680
Опубликована: Май 10, 2024
Spinal cord injuries lead to significant loss of motor, sensory, and autonomic functions, presenting major challenges in neural regeneration. Achieving effective therapeutic concentrations at injury sites has been a slow process, partly due the difficulty delivering drugs effectively. Nanoparticles, with their targeted delivery capabilities, biocompatibility, enhanced bioavailability over conventional drugs, are garnering attention for spinal treatment. This review explores current mechanisms shortcomings existing treatments, highlighting benefits progress nanoparticle-based approaches. We detail nanoparticle methods injury, including local intravenous injections, oral delivery, biomaterial-assisted implantation, alongside strategies such as drug loading surface modification. The discussion extends how nanoparticles aid reducing oxidative stress, dampening inflammation, fostering regeneration, promoting angiogenesis. summarize use various types treating injuries, metallic, polymeric, protein-based, inorganic non-metallic, lipid nanoparticles. also discuss faced, biosafety, effectiveness humans, precise dosage control, standardization production characterization, immune responses, vivo. Additionally, we explore future directions, improving standardizing manufacturing characterization processes, advancing human trials. Nanoparticles have shown considerable enhancing treatment efficacy potential clinical development.
Язык: Английский
Процитировано
8
European Journal of Medicinal Chemistry Reports, Год журнала: 2025, Номер unknown, С. 100268 - 100268
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
1
Phytomedicine, Год журнала: 2023, Номер 122, С. 155150 - 155150
Опубликована: Окт. 15, 2023
Язык: Английский
Процитировано
12
Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, Год журнала: 2024, Номер 16(1)
Опубликована: Янв. 1, 2024
Abstract Microbial biofilms are complex three‐dimensional structures where sessile microbes embedded in a polymeric extracellular matrix. Their resistance toward the host immune system as well to diverse range of antimicrobial treatments poses serious health and development threat, being top 10 global public threats declared by World Health Organization. In an effort combat biofilm‐related microbial infections, several strategies have been developed independently eliminate or complement conventional antibiotic therapies. However, their limitations leave room for other treatment alternatives, application nanotechnology biofilm eradication has gained significant relevance recent years. small size, penetration efficiency, design flexibility that they present makes them promising alternative infection treatment, although also set‐backs. This review aims describe main possibilities nanomedicine against biofilms, while covering aspects formation study, current therapies treatment. article is categorized under: Therapeutic Approaches Drug Discovery > Nanomedicine Infectious Disease Toxicology Regulatory Issues Nanomaterials Policy
Язык: Английский
Процитировано
4
Chemical Engineering Journal, Год журнала: 2024, Номер 494, С. 153171 - 153171
Опубликована: Июнь 15, 2024
Язык: Английский
Процитировано
3
Dalton Transactions, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
The use of bismuth and its compounds in biomedicine has developed rapidly recent years. Due to their unique properties, there are great opportunities for the development new non-invasive strategies early diagnosis effective treatment cancers. This perspective highlights key fabrication methods generate well-defined clinically relevant materials varying characteristics. On one hand, this opens up a wide range possibilities unimodal multimodal imaging. other strategies, which increasingly based on combinatorial therapies, given deal attention. One biggest challenges remains selective tumour targeting, whether active or passive. Here we present an overview developments moving forward from simple enrichment at site via uptake by mononuclear phagocytic system (MPS) more specific targeting covalent modification with tumour-seeking molecules either small antibody-derived molecules.
Язык: Английский
Процитировано
0